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Abstract
The review attempts to determine the effects of Lactobacillus genus
supplementation on weight and weight related factors. A literature review produced nine
studies that met selection criteria. Of the nine articles included in the review, eight of
them demonstrated weight loss among the study population after supplementation with
Lactobacillus species. To initiate routine supplementation of Lactobacillus species in
dietetic practice additional research is need to better understand mechanisms of action,
optimal dosage, impact of varied macronutrient composition, and timeframe required for
supplementation.

Introduction
Obesity continues to be a health concern not only in the United States, but
worldwide. In just over three decades, the prevalence of obesity has nearly doubled
worldwide with 11% of men and 15% of women aged 18 and over being classified as
obese in 2014.1 It is well established that obesity is impacted by genetic, lifestyle, and
socioeconomic factors; however there appears to be an association between the gut
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microbiome and weight. The human intestinal microflora represents a complex
ecosystem that is composed of trillions of microorganisms that function in host
metabolism.2 The association between the intestinal microflora and host metabolism
was first discovered when an obese phenotype was produced in lean mice species after
being transplanted with the intestinal microflora from obese mice.4 There are several
proposed mechanisms by which the intestinal microflora may impact body weight,
including the efficiency of energy extraction, modulation of energy intake and
metabolism, and regulation of satiety hormones and gut motility.2 As such, there is
increasing interest in the use of probiotics to modify weight in obese individuals.
Probiotics are living microorganisms that when consumed have the ability to confer a
health benefit.3 Bacterial species belonging to the genus Lactobacillus and
Bifidobacterium have been among the most commonly investigated probiotics in
association with changes in adiposity.
There are in general four theories on potential mechanisms through which
Lactobacillus species may influence obesity phenotype, including: (1)The intestinal
microflora of obese subjects are more efficient at extracting energy from a given diet
when compared to the intestinal microflora of lean individuals, thus leading to increased
energy storage and adiposity.4 (2) The intestinal microflora produce short chain fatty
acids from fermentation of indigestible polysaccharides. The SCFA such as acetate,
butyrate, and propionate function as both energy substrates and regulators of satiety
and food intake. SCFA activate G-protein-coupled receptors GPR41 and GPR3 on
intestinal epithelial cells and consequentially stimulate peptide YY and glucagon-like
peptide (GLP)-1 secretion. These hormones are responsible for suppressing gut
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motility, extending transit time and thus allowing for greater nutrient absorption. (3)
Conjugated linoleic acid (CLA) includes a mixture of linoleic acid isomers with
conjugated double bonds that are a result of incomplete biohydrogenation of the
unsaturated fatty acid linoleic acid. Humans are incapable of producing CLA from
linoleic acid, thus the amount of CLA in human adipose tissue is directly related to the
consumption of dietary CLA. Dietary sources of CLA include beef and dairy products
such as milk fat, cheese, yogurt, and plant oil. It has been suggested that CLA may
provide beneficial anti-carcinogenic activity, anti-arterogenic activity, ability to reduce
catabolic effects of immune stimulation, and ability to reduce body fat. Synthesis of CLA
which has anti-obesity properties.2 (4) The inhibition of pro-inflammatory CCL2 and
TNF-alpha are largely responsible for the anti-obesity effect of lactobacillus.7 Research
has suggested that a deficiency in the CCL2-CCR2 axis results in a reduction in visceral
adipose tissue mass. Consequentially, reduced up-regulation of CCL2 and CCR2, as
well as their regulator TNF-alpha may be proposed as a mechanism responsible for the
reduction in visceral adipose tissue mass after consumption of lactobacillus. Of
additional note inflammation in the adipose tissue is also closely related to the
regulation of inflammation in the intestine.

Methods
The literature review was initiated by using search engines Ebscohost and
CINAHL and keywords obesity and lactobacillus. Results were narrowed by selecting
studies published between 2014 and 2019 in peer-review journals. There were not
limitations with regards to study design; however study topic was limited to change in
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obesity phenotypes. Those studies that did not include assessment of changes in
obesity phenotype were excluded from the review. Thus this review does not address
the effect of Lactobacillus species on obesity-related factors such as hyperlipidemia and
insulin resistance. Duplicates were manually identified and eliminated. All human
studies included adult subjects, greater than 18-years of age and were classified as
overweight or obese according to BMI. All articles obtained were written in the English
language.

Discussion
Lactobacillus Rhamnosus
In the study conducted by Lee, et al. mice fed L. rhamnosus demonstrated
decreased weight gain notable to the epididymal white adipose tissue despite lack of
variance in energy intake compared to control group.4 This effect is thought to be a
result of the continuous production of CLA after colonization in the gut. Previous studies
have consistently supported that idea that CLA supplementation induces a significant
decrease in body fat deposition without significant reduction in caloric intake. Fat
deposition changes are thought to be related to decrease in the number of fat cells
rather than changes in the cell size. While beneficial effects on body weight were
observed in subjects fed Lactobacillus rhamnosus PL60, there did not appear to be any
dose dependent effect between those that received 1 x 107 (PL60L) or those that
received 1x109 (PL60H) CFU daily, despite the presence of serum CLA in the group
receiving 1x109. Longevity of the study is only 8 weeks; however reduction in body
weight with administration of both PL60H and PL60L became narrower over the study

4

period, suggesting that the dose used was sufficient to convey a maximal effect.
Additionally, this study does not explore that need for continued supplementation or the
required dose of PL60 to maintain weight loss benefits.
Similarly, the double-blind, placebo-controlled, randomized trial by Sanchez et
al., conveys similar benefits on weight loss of the Lactobacillus rhamosus species only
in the human population.5 Over the course of 24 weeks study subjects consumed two
capsules per day of either a placebo or Lactobacillus rhamnosus CGMCC1.3724 (LPR)
formulation which contained 1.6 x 108 colon-forming units of LPR per capsule with
oligofructose and inulin while adhering to a moderate energy restriction for 12-weeks
(500 calories/day), followed by 12-weeks of maintenance. The trial found no significant
change in weight loss during the energy-restriction or after the weight maintenance
period. There was also no significant difference in fat mass. There were however
significant variances when evaluating treatment x sex interaction. Specifically, during
phase 1, there were more significant reductions in body weight and fat mass in the LPRtreated women than in the placebo-treated women. Additionally, at the end of phase 2
reductions in body weight and fat mass were more pronounced in the LPR-treatment
women than in the placebo-treated women. Body weight and fat mass were not
significantly affected by treatment in men. There were no significant differences on
metabolic and inflammatory plasma markers during the trial period with the exception of
leptin. At week 24, there was a greater decrease in fasting leptin concentrations among
both men and women in the LPR group when compared with the placebo group. This
suggests that there is a change in weight or metabolism as it is thought that leptin levels
are associated with reduced energy stores and brain control of eating behaviors.6
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Traditionally, leptin levels decrease during weight loss and encourage feeding,
reduction in energy expenditure, and promotion of weight regain. Thus the there
remains the question of longevity and ability for Lactobacillus rhamnosus to continue to
suppress appetite despite weight loss and reduced leptin levels. While the study
accounted for caloric intake and capped amount of probiotic-enriched products, it did
not control for other lifestyle factors that may impact weight such distribution of
macronutrients, intake of fiber, sugar, and fluids, sleep pattern, genetics, and exercise.
Interestingly, the study did account for gastrointestinal factors that may affect the
viability and efficacy of probiotic supplement capsules and added oligosaccharide and
polysaccharide mixture to accommodate. Both oligosaccharides and polysaccharide are
prebiotics which may exhibit there own selective benefits or enhance probiotic effects;
however the study suggests that they did not likely have any independent effect on the
LPR group.
Both the study conducted by Lee et al. and Sanchez et al. suggest a positive
benefit to Lactobacillus rhamnosus on weight status. The Lee et al. trial did not
differentiate between male and female species; however the Sanchez et al. trial
suggested that supplementation with the Lactobacillus rhamnosus species benefits only
women in the timeframe allotted, which provide strong evidence of the benefit of LPR
supplementation.
Lactobacillus gasseri
The study included C57BL/6 mice that were divided into three groups: those fed
a 5%-fat diet, 10%-fat diet, and 10%-fat diet containing the probiotic LG2055 (10% fatLG).7 The mice were allowed free access to their respective diet for 24 weeks. Weight,
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fat tissue mass, liver fat content, and inflammatory genes in adipose tissue, and
lipogenic and lipolytic genes in the liver were then assessed. As expected, the mice fed
the 10%-fat group had a significantly higher energy intake compared with the group fed
a 5%-fat diet. Initial body weights were similar among the groups; however the final
body weight in the 10%-fat group was significantly higher compared to the 5% fat group.
The 10% fat-LG group demonstrated a significantly lower final body weight compared
with the 10% fat group despite having similar energy intake. Additionally, the 10% fatLG group had significantly lower relative weight of the retroperitoneal fat and epididymal
compared with the 10% fat group. Triglyceride levels in the liver were significantly
elevated in the 10% fat group compared with the 5% fat group and generally lower in
the 10% fat-LG group compared with the 10% fat group. Additionally, the epididymal
adipose tissue of the 10% fat group demonstrated higher expression levels of proinflammatory genes and adipocytokine gene, leptin when compared with the 5% fat
group. In the liver, the 10% fat group offered higher expression of lipogenic genes, such
as acetyl CoA carboxylase 1, fatty acid synthase, and sterol regulatory element-binding
protein 1 compared with the 5% fat group and the 10% fat-LG group demonstrated
levels similar to the 5% fat group. The 10% fat-LG group also demonstrated reduced
levels of tumor necrosis factor alpha when compared with the 10% fat group. The
results suggest that the inhibition of pro-inflammatory CCL2 and TNF-alpha are largely
responsible for the anti-obesity effect of lactobacillus. Of additional noted, the
expression of FAS, which is lipogenic, decreased in the 10% fat-LG group compared
with the 10% fat group. In summation, the LG2055 is thought to decrease lipogenesis
and increased lipolysis in the liver; however the results in this study were not significant.
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The results may have been impacted by the type of fat used in the study groups.
The 10% fat diet was comprised of lard compared with the 5% fat group, which utilized
corn oil. The corn oil contains less saturated fatty acids than the lard. The higher
concentration of linoleic acid in the corn oil may lead to intestinal inflammation which
may in turn obscure the significance of the pro-inflammatory effects caused by higher
calorie and fat consumption in the 10% fat groups. Additionally the long study period
may have allowed for the intestine to adapt to low-grade inflammation, thus it may be
more beneficial to assay pro-inflammatory markers at periodic intervals throughout the
study.
Kadooka et al. conducted a multi-center, double-blind, randomized, placebocontrolled trial that included 87 generally healthy adults.8 The study period included a 4week lead-in period, followed by a 12-week consumption period in which subjects
consumed either the fermented milk product containing 10^8 colon-forming units (CFU)
of LG2055 or a control fermented milk-lacking LG2055. Subjects consumed 100 g twice
a day of the active or control fermented milk for 12 weeks. Despite consistency in
activity level, macronutrient composition, and total calorie intake among test subjects,
there was a significant decrease in the visceral, subcutaneous, and total fat areas in the
active group between week 0 and week 12; however there were no significant changes
noted among the control group. Additionally, the active group demonstrated significant
decreases from week 0 in the following parameters at the stated time points: body
weight at W8 and W12, BMI at W8 and W12, waist circumference at W8 and W12, hip
circumference at W8 and W12, and waist-to-hip ratio at W8. Conversely, the control
group did not show any significant decreases in any of the parameters.
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The study period is not sufficient to demonstrate continued effects of the probiotic
supplement, nor is it sufficient to allow for a plateau in the study results. Thus, it would
beneficial to prolong the study period to determine the timeframe required to obtain
optimal supplement results and the ability to persist beneficial results in weight and
adipose tissue after a plateau is obtained among participants. The trial accounts for
factors such as macronutrient intake, total calorie intake, and exercise; however it does
not account for other factors such as stress, sleep, and genetics, which may impact
study results. Lastly, the fermented milk contains beneficial components such as
calcium and conjugated linoleic acid, which may also positively benefit weight and
obesity status; however both calcium and conjugated linoleic acid were common to both
groups and thus not likely to have contributed to any of the documented benefits.
After demonstrating favorable benefits of fermented milk with 108 colony-forming
units (CFU) of Lactobacillus gasseri supplementation in individuals with obese
tendencies, Kadooka et al. attempted to explore a potential minimum CFU required to
yield positive changes in obesity phenotype in a multi-center, double-blind, parallelgroup, randomized-control group that included 210 Japanese adults with significant
visceral fat areas.9 The study period involved a 4-week lead-in period, followed by a 12week consumption period, and a 4-week post-consumption period. Subjects consumed
one of three products: (1) fermented milk containing 107 CFUs, (2) fermented milk
containing 106 CFUs, or fermented milk containing 0 CFUs, for 12 weeks while
maintaining usual diet and exercise. There were no significant differences in abdominal
subcutaneous fat areas; however visceral fat decreased significantly at weeks 8 and 12
from baseline in the active group. Additionally, BMI, waist, and hip circumferences were
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significantly reduced in both the 107 and 106 dose groups at week 8 and 12 from
baseline; however at 4 weeks after the completion of consumption, the amount of
changes in all measures in both the 107 and 106 dose groups became smaller than
observed at week 12. Only fat mass demonstrated a significant decrease at week 12
both from baseline and against the control in both the 107 and 106 dose groups;
however the significance from baseline disappeared at 4-weeks after complete
consumption.
Contrary to previous studies, Kadooka demonstrates a peak of effects on BMI
and waist and hip circumference. The study also suggests that without continued
supplementation of the Lactobacillus product the achieved benefits cannot be
maintained for more than four weeks. All three products were identical with the
exception of the Lactobacillus, thus nutrients such as calcium and fat content would
have contributed that same effect on all subject groups. Consequentially, it can be
assumed that the results of the study are a result of the Lactobacillus. Lastly, similar to
other studies included the review, there is no control for other various lifestyle factors
including diet, exercise, sleep, stress, and inactivity that may influence weight related
factors.

Lactobacillus acidophilus
Arora et al. confused a study that included 24 male C57BL/6 mice were first acclimated
to a normal chow diet for one week.10 Following the acclimation period, mice were
randomized according to weight and divided into two groups: control dahi and probiotic
dahi. The viable counts of viable counts of L. acidophilus in the probiotic dahi were in
10

the range of 5 x 107 to 9 x 107 CFU/ml. The only difference between the control and the
test samples was the addition of L. acidophilus. Both groups were fed a 21% high-fat
diet and their respective dahi products for eight weeks. The probiotic group had no
significant changes in body weight or food intake. Additionally, there were no significant
differences in visceral or subcutaneous fat deposits by MRI between the control and the
probiotic dahi-fed mice. There was however a significant increase in the fecal
Bifidobacterium counts in the control and probiotic-fed groups at week 8. Additionally,
the control group experienced a significant decrease in Lactobacillus-Enterococcus at
week 8 compared with week 1; however there was no significant difference observed in
total bacteria. There observations may suggest that Lactobacillus acidophilus species
was ineffective in colonizing the intestinal walls and proliferating in the intestinal
environment under high dietary fat conditions. It may have also been that the dose of
Lactobacillus acidophilus was insufficient to encourage colonization and proliferation.
While Arora et al. did not demonstrate any changes to obesity related factors with
supplementation of Lactobacillus acidophilus, there were a number of study flaws
including the small population size limited to just males and lack of information
regarding weight status. In the event that all mice were of normal weight and adiposity,
it would be difficult to demonstrate changes to weight and adipose tissue with
supplementation of Lactobacillus acidophilus. Additionally, the range of the viable
Lactobacillus acidophilus was too large to determine sufficient dose required to produce
desired results. The study would be difficult to reproduce with the variance in CFUs
amount in samples provided to subjects. While the study used a medium that already
contained beneficial bacteria, Lactococcus, the results are likely a result of the
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Lactobacillus acidophilus as both the control and the test products were the same with
the exception of the addition of the Lactobacillus acidophilus in the test product.
Additional research is necessary to further investigate potential benefits of Lactobacillus
acidophilus on weight related factors.
Lactobacillus reuteri
The study included 10 rats that were fed a normal diet and placebo (distilled water).10
The remaining 30 rats were fed a high-energy diet (HED) and were then randomly
assigned to one of three groups, including the HE group, the 1X group (HED and 2.1 x
109 CFU/kg/day of L. reuteri 263) and the 5X group (HED and 1.05 x 1010 CFU/kg/day
of L. reuteri). Daily food and water intake, weekly weights adipose tissue, biochemical
profiles, adipocyte, and oxygen consumption rate were assessed. The food energy
intake was higher in the HED-fed rats than the normal-fed diets and subsequently the
average body weight of the HE group increased the most. The body weight of the 1X
group was slightly higher than the 5X group. The control group had the smallest
increase in body weight. The HE group demonstrated significantly higher levels of
fasting blood sugars, triglycerides, total cholesterol, and LDL compared to the other
groups. Additionally, the HE group also had the lowest HDL compared to either of the
other groups. The level of the inflammatory factors IL-6 and TNF-alpha were 2 and 1.5
times higher in the HE group, while the 1X and 5X group had significantly higher levels
than the control group. As expected, the control group had the lowest percentage body
fat; however the HED-derived high percentage body fat was modulated with
administration of daily doses of L. reuteri 263. The HE group also had the highest
weight for EFPs, renal fat pads, and mesenteric fat pads, followed by the 1X, 5X, and C
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groups, respectively. Lastly, the 5X group had the highest bioenergetic health index
(BHI), approximately 1.4 times that of the C group and 2.7 time the HE group. The
potential benefit effects of L. reuteri may be related to the upregulation of mitochondrial
respiration in white adipose tissue (WAT) following oral L. reuteri 263.
The study sample was limited to 8-week old male mice with no evidence of obesity at
baseline. Of the studies collected, Chen et al. was the only to assess WAT and the
oxygen consumption of WAT, which plays an importance role in anti-obesity. WAT is
typically viewed as an energy-storing tissue, but has demonstrated the ability to
dissipate energy and upregulate energy expediting genes such as Ucp 1, Ucp3, Cpt1α,
and Cidea. The variance in WAT among study groups and the increase in energy
expediting genes in the 5X group suggest that energy remodeling of WAT may improve
obesity. L. reuteri may induce the WAT browning pathway by regulating cytokines, gut
peptides, and neurotransmitters in the gut to influence the development and behavior of
the brain. In turn the brain can increase the browning of WAT by activating the
sympathetic nervous system innervation. This process is referred to as the gut-brain
axis.
In Summary, Lactobacillus rhamosus and Lactobacillus gasseri appear to be the most
prominent Lactobacillus genus to benefit weight status among both rats and humans.
Supplementation with Lactobacillus rhamosus decreased weight in rats and yielded
significant reductions in weight and fat mass among only women.5,6 Both men and
women experienced a decrease in fasting leptin levels, which may suggest a possible
mechanism behind the benefit of Lactobacillus rhamosus on weight related factors.6
Lactobacillus gasseri supplementation appeared to protect against weight gain and
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accumulation of epididymis and retroperitoneal fat stores despite energy intakes similar
to those receiving an identical diet.7 Additionally, the supplementation of Lactobacillus
gasseri discouraged an increase in lipogenic genes in rats. In the human population,
Lactobacillus gasseri supplementation produced significant decreases in visceral,
subcutaneous, and total fat areas, as well as significant decreases in total body weight,
waist-to-hip ratio, hip circumference, and waist circumference at various points
throughout the study in the absence of dietary or lifestyle changes.8 Kadooka et al. also
demonstrated that 106 CFUs is sufficient to yield positive results. Lactobacillus reuteri
appears to protect against fat accumulation and weight gain in rats; however those
subjects on a regular diet without probiotic supplementations maintained the lowest
weight and fat deposits.11 The species Lactobacillus acidophilus did no produce any
benefits with regard to weight; however additional studies are necessary to further
investigate potential to influence weight.
While the review suggests that the Lactobacillus genus has great potential to moderate
weight, fat deposition, and other weight related factors, there are a number of
shortcomings of the reviewed studies. Off the studies, with the exception of one, had a
small population size consisting of less than 100 subjects. While all studies included a
washout period, there were lifestyle factors such as calorie intake, exercise length and
intensity, and amount and/or quality of sleep that were not controlled during the study
period. The animal studies reviewed replicate the high-fat diet of a typical western USA
diet with the average fat content of approximately 33%; however the studies do not
reflect the high levels of refined sugars and oils that are often consumed regularly by
most Americans.12 Consequentially, the impact of varied nutrient intake may alter the
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results of conducted trials. Lastly, all of the studies included in the review lacked the
ability to demonstrate the need for continued supplementation to sustain weight and fat
deposit changes. Only a limited number of studies demonstrated a plateau with
supplementation, thus suggesting that benefits were no optimized with the timeframe of
the study. Understanding the impact and efficacy of Lactobacillus strains on weight
would yield a valuable resource for Registered Dietitians working with overweight and
obese individuals.
Conclusion
In conclusion, there appears to be an inverse relationship between supplementation
with the Lactobacillus species, including Lactobacillus gasseri, Lactobacillus rhamosus,
and Lactobacillus reuteri on weight status, fat accumulation, and weight related factors;
however more research is necessary to determine mechanisms of action, optimal
dosage, impact of varied macronutrient composition, and timeframe required for
supplementation. Ongoing research regarding the Lactobacillus genus would increase
opportunities for Registered Dietitians to impact weight management success in
overweight and obese individuals. Further research may also unveil other information
regarding the benefits of various species on the microbiome and subsequent health
benefits and respective mechanisms. With a greater understanding of the microbiome
and the impact of supplementation with the Lactobacillus genus and other probiotics,
would further emphasis the necessity of dietitians as part of the healthcare team.
Exploration of probiotics and the microbiome is a great opportunity for dietitians to
encourage all individuals to explore the impact of all foods and nutrients on the diverse
microbiome.
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